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Abstract
Background: The development and progression of human tumors is accompanied by various cellular,
biochemical and genetic alterations. These events include tumor cells interaction with extracellular matrix
molecules including hyaluronan (HA). Hyaluronan is a large polysaccharide associated with pericellular
matrix of proliferating, migrating cells. Its implication in malignant transformation, tumor progression and
with the degree of differentiation in various invasive tumors has well accepted. It has been well known the
role HA receptors in tumor growth and metastasis in various cancer tissues. Previously we have observed
the unified over expression of Hyaluronic Acid Binding Protein (HABP), H11B2C2 antigen by the tumor
cells in various types progressing tumor tissues with different grades. However, the poor understanding
of relation between HA and HA-binding protein expression on tumor cells during tumor progression as
well as the asymmetric observations of the role of HA expression in tumor progression prompted us to
examine the degree of HA expression on tumor cells vs. stroma in various types of human tumors with
different grades.
Methods: In the present study clinically diagnosed tumor tissue samples of different grades were used to
screen the histopathological expression of hyaluronan by using b-PG (biotinylated proteoglycan) as a probe
and we compared the relative HA expression on tumor cells vs. stroma in well differentiated and poorly
differentiated tumors. Specificity of the reaction was confirmed either by pre-digesting the tissue sections
with hyaluronidase enzyme or by staining the sections with pre-absorbed complex of the probe and HA-
oligomers.
Results:  W e  s h o w  h e r e  t h e  d o w n  r e g u l a t i o n  o f  H A  e xpression in tumor cells is associated with
progression of tumor from well differentiated through poorly differentiated stage, despite the constant HA
expression in the tumor associated stroma.
Conclusion: The present finding enlighten the relative roles of HA expression on tumor vs. stroma during
the progression of tumors.
Published: 10 January 2006
Journal of Carcinogenesis 2006, 5:2 doi:10.1186/1477-3163-5-2
Received: 05 February 2005
Accepted: 10 January 2006
This article is available from: http://www.carcinogenesis.com/content/5/1/2
© 2006 Boregowda et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
Page 2 of 9
(page number not for citation purposes)
Background
Hyaluronan (HA) is a ubiquitous component of the extra-
cellular, pericellular and intracellular matrices that medi-
ates cell proliferation, migration, developmental,
differentiation, morphogenetic processes in the develop-
ing organs, inflammation and tumor development [1].
Hyaluronan is structurally a simple primitive molecule. It
is a large linear glycosaminoglycan composed of uni-
formly multiple repeats of β-1,3 N-acetylglucosaminyl
and β-1,4 glucuronide disaccharide unit mainly produced
by the stromal cells and it is distributed in various com-
partments of tissues [10]. HA's physicochemical proper-
ties contribute to the formation of space which aids in the
tumor cells migration and infiltration of newly formed
blood vessels [18]. The presence of HA is well evidenced
in the cytoplasm and nuclei of the cells in a number of tis-
sues in vivo to modulate the cell behavior by interacting
with specific cell surface receptor- hyaluronic acid binding
proteins (HABPs) known as Hyaladherins. This phenom-
enon also plays an important role in maintaining and sta-
bilizing the structural integrity of extracellular matrices [2-
4]. Recent studies have shown that there are a number of
HA-binding proteins that may be important in the regula-
tion of cell cycle or gene transcription [5-8]. It is an estab-
lished fact that most malignant tumors such as colon
carcinoma [11], breast carcinoma [12] gliomas [13], lung
carcinomas [14,15] and wilms' tumors [16] contain ele-
vated levels of HA than their normal counterparts. The
distribution of HA in normal esophagus, stomach, colon
and in adenocarinomas of these tissues was ruled out as a
possible indicator for differentiation process [17]. The
increased metastasis behavior of mouse mammary carci-
noma [19] and melanoma cells [20] has been related to
increase HA synthesis by tumor cells.
In tumor tissues, HA promotes tumor metastasis by open-
ing up spaces for tumor cells to migrate and actively sup-
ports tumor cell migration by interacting with cell surface
HA receptors [47]. Previously, our immuno histopatho-
logical detection of the continuous over-expression of
HA-binding protein in correlation with tumor progres-
sion in human tumors of different origin with different
grades identified the role of HA-binding protein as a prog-
nostic indicator [9]. In this context, one might assume the
down- regulation of tumor cell surface and intracellular
HA with respect to tumor progression in relation with
increased expression of Hyaluronidase enzyme by the
tumor cells. This has raised the question about the fate of
HA on the tumor cells and its role in tumor progression
and invasion in to the stroma. In accordance with this
concept it has been reported the high expression of HA in
tumor associated stroma and increased HYAL-1 (Hyaluro-
nidase) enzyme synthesis on tumor epithelial cells in
high-grade prostate carcinoma [48]. The weak correlation
between tumor cell hyaluronan and its perineural inva-
sion as well as the prognostic value of stromal hyaluronan
has been reported with metastasis in prostate cancer [49].
Despite the reports concerning the role of tumor vs. stro-
mal hyaluronan in tumor progression, there was no clear
evidence of its role in all the possible human tumors. In
the present study we have screened the twenty one differ-
ent types of progressing tumors of epithelial carcinomas,
sarcomas and carcinomas of different origins with a spe-
cific probe for the localization and distribution of
hyaluronan in tumor epithelia and intra-tumoral regions
as well as benign areas. The results showed considerable
up-regulation of hyaluronan in well differentiated tumors
and associated stroma irrespective of their origin, while it
is down-regulated in poorly differentiated tumors by
retaining constant stromal hyaluronan expression. This
study served as the explanation of the role of HA expres-
sion in tumor progression and invasion process as well.
Methods
The study group consisted of 256 different samples. The
samples were collected after surgery from cancer patients
of different age groups at a local hospital between 1995
and 2002 after the approval of ethical committee from the
hospital. The case history and diagnosis undertaken were
recorded during sample collection. All the samples
showed low to high-grade tumors and both malignant
and normal areas were examined in all the cases. The tis-
sues from biopsies were fixed as soon as possible in 10%
buffered formalin and processed by the standard proce-
dure. Paraffin blocks were made and 3 to 5 micron sec-
tions were cut and used for the histochemical analysis of
HA. Specimens were selected based on the presence of
both benign and malignant histology, present within the
same tumor sections. All tissue sections were initially
stained with hematoxylene and eosine method to evalu-
ate the grades of the tumors. In all cases, routine inde-
pendent pathological diagnosis was made in the
pathology laboratory. Malignant tumors were classified as
well differentiated (grade-I); moderately differentiated
(grade-II); and poorly differentiated (grade-III) based on
their level of differentiation.
Localization of hyaluronan
Histochemical localization of hyaluronan was carried out
by using a biotinylated HA-affinity probe. The tissues were
incubated with the biotinylated probe which consisted of
a mixture of cartilage proteoglycan core protein and link
protein (kindly provided by Charles Underhill; Depart-
ment of Anatomy and Cell Biology, Georgetown Univer-
sity and by Dr Bryan Toole; Department of Cell Biology
and Anatomy, Medical University of South Carolina,
Charleston, USA and purchased from Calbiochem,
U.S.A.) at a concentration of 5 µg/ml which recognizes
hyaluronan in tissues. Hyaluronan staining from 5 days
old chicken embryonic limb tissue section (that has beenJournal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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processed like all other human tissues) was used as a pos-
itive control. The specificity of HA staining was confirmed
by incubating tissue sections with either streptomyces or
bovine testicular hyaluronidase (50 U/ml in acetate buffer
pH 5.0, overnight at 37°C) prior to the incubation with
the HA-affinity probe. In the second set of experiments
the specificity of HA staining was additionally confirmed
by staining the tissue sections with a pre-incubated com-
plex of biotinylated PG with 100 µg/ml hyaluronan or
300 ug HA-oligomers. In all the cases the probe was
applied in PBS containing 1% BSA for 2 hours at room
temperature, the slides were washed in PBS and processed
as described below.
Chromogen treatment
In all cases, the slides were subsequently incubated with
streptavidin-horseradish peroxidase conjugate (Bangalore
Genei, Karnataka, India) for 1 hour at room temperature.
The color reaction was developed for 15 minutes using
diaminobenzidine hydrochloride (DAB) in 0.1 M Tris-Hcl
pH 7.4. The substrate solution was freshly prepared by
dissolving 6.0 mg DAB in 15 ml of 0.1 M Tris buffer, then
4.5 µl of 30% H2O2 was added just before use. The slide
was rinsed in distilled water, sequentially dehydrated in
graded alcohol and mounted in DPX mounting media.
Photographs were taken with a Leica Photovat micro-
scope.
HA expression in well differentiated tumors Figure 1
HA expression in well differentiated tumors: Only 8 
examples are shown. Top row, (A, B, C) represents cere-
bral astrocytomas, ganglioglioma and salivary gland tumor. In 
astrocytomas neuroglial fibers and the astrocyte membrane 
are highly reactive for HA. Neoplastic nerve cells with exten-
sive fibrillar processes are HA positive in ganglioglioma. 
Benign epithelia surrounding the tumor cells in salivary of 
showed low HA reaction. Middle row, (D, E, F) repre-
sents papillary carcinoma of thyroid, infiltrating breast and 
stomach tumor. Thyroid tumor showed intense HA staining 
at intraepithelial and in surrounding stromal components. 
High level HA expression was observed in tumor cells and 
surrounding stroma in case of infiltrating breast tumor. 
Tumor epithelia of stomach showed strong HA reaction. 
Bottom row, (G, H, I) represents Transitional epithelia of 
urinary bladder, descending colon and 5 days old chicken 
embryo limb. Transitional epithelia of urinary bladder 
showed intense staining at intra-epithelial and in surrounding 
tumor components. Invasive colon tumor cells showed 
strong HA reaction. 5 days chicken embryo limb was used as 
positive control, where the mesoderm is intensely positive 
for HA. Arrow shows the tumor cells and the asterisk shows 
stroma. Scale bars, 50 µm.
HA expression in poorly differentiated tumors Figure 2
HA expression in poorly differentiated tumors: Only 8 
examples are shown. Top row, (A, B, C) shows disappear-
ance of HA stain from the tumor epithelia. Fibrillar astrocy-
tomas show intense reaction while astrocytes are negative. 
Infiltrating breast and stomach tumor epithelia shows the 
loss of HA while the stromal components shows intense HA 
stain. Middle row, (D, E F) shows the loss HA expression 
in urinary bladder, pancreas (tumor epithelia) and caecum 
tumor epithelia while the stromal areas from urinary bladder 
and caecum were enriched with HA positive materials. Bot-
tom row, (G, H) represents prostate and ovary. Prostate is 
showing numerous invading tumor cells in stromal areas. 
Only the stromal components are stained with b.PG. Ovary 
shows total absence of HA expression in tumor cells while 
the stroma is enriched with HA. Arrow shows the tumor 
cells and the asterisk shows stroma. Scale bars, 50 µm.Journal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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Results
Hyaluronan localization in embryonic limb bud
In the present study we have used 5 days chicken limb bud
as an illustrative model and as a positive control to dem-
onstrate the presence of hyaluronan. It is well known that
early limb mesoderm cells are surrounded and separated
by a hyaluronan rich matrix33. Fig 1 (I) shows the pres-
ence of highly enriched hyaluronan positive mesodermal
cells in the chick embryo limb bud.
Hyaluronan expression in well differentiated tumors
We have screened more than 20 different well differenti-
ated tumors. The tumor tissue sections were deparaffin-
ized, processed and stained with b.PG probe as explained
in the materials and method section. There are 8 examples
shown in Fig. 1. Astrocytoma, salivary gland, thyroid,
infiltrating breast, stomach, urinary bladder and colon
tumors are well differentiated (grade 1) (Fig
1A,C,D,E,F,G,H) and ganglioglioma (grade II) (Fig. 1B) In
all the tumors intense hyaluronan staining was found
both in the tumor cells, intra-tumoral and in the associ-
ated surrounding stroma.
Hyaluronan expression in poorly differentiated tumors
Out of 20 tumors studied we have presented 8 examples
of highly advanced poorly differentiated tumor tissues
here. The tissues were astrocytomas, infiltrating breast,
stomach, gall bladder, pancreas, caecum, prostate, ovary
(Fig. 2A to 2H). In all cases of epithelial carcinomas or sar-
comas, the tumor cells showed almost complete lack of
hyaluronan stain. However, the intratumoral and stromal
areas showed moderate hyaluronan stain.
Specificity of b.PG for hyaluronan staining
The tumor tissues were either treated with hyaluronidase
at 50 units/ml or bPG pre-absorbed with 300 µg/ml
hyaluronan-oligomers. Irrespective of their origin the
tumor showed negative staining of HA in the tumor epi-
thelia or stromal area. Fig. 3A to 3E. shows Thyroid, Infil-
trating breast, Pancreas, Descending Colon and Urinary
bladder with the lack of HA staining.
Hyaluronan expression in stroma
Intense hyaluronan staining was observed in intra and
peritumoral areas of all the well differentiated tumors
when compared to the benign areas. Carcinomas from
astrocytomas, gangliogliomas, thyroid, breast and salivary
showed intense accumulation of hyaluronan in intratu-
moral areas. Highly aggressive poorly differentiated
tumors of different origins showed moderate to low levels
of stromal hyaluronan in the immediate vicinity the
tumor cells (Fig. 4A to 4H). High levels of stromal staining
in highly -differentiated and moderate staining in poorly
differentiated tumors stroma may indicate the role intra-
tumoral and tumor associated stromal components in
maintaining the progressive nature of the tumors.
Tumor cell associated hyaluronan expression
Epithelial cells of benign areas were mostly hyaluronan
negative. In the 20 tumors studied, epithelial cells surface
were highly positive for HA in the well differentiated than
in the poorly differentiated tumors. Only 3 examples are
illustrated in Fig (5A,B and 5C) demonstrates the localiza-
tion of hyaluronan on the plasma membrane.
Discussion
The purpose of the present study was to investigate the HA
expression in tumor cells and in intratumoral stromal
areas in different types of tumor tissues with different ori-
gins and to reveal the possible role of HA involvement
with progressive malignant behavior. Our results from 23
tumor tissues of different grades showed the down-regula-
tion of HA expression in tumor epithelial cells during later
stages of all types of malignancies irrespective of their ori-
gin. On the contrary, all highly differentiated tumors such
as Astrocytomas, gangliogliomas, thyroid, lung, salivary,
breast, esophagus, stomach, pancreas, colon, rectum, gall
bladder, kidney, urinary bladder, prostate, testes, ovary,
Specificities of b.PG for HA staining Figure 3
Specificities of b.PG for HA staining: Only 5 examples 
are shown. A. Thyroid, B. Infiltrating breast, C. Pancreas, D. 
Colon and E. Urinary bladder. All tumors are negative for 
Hyaluronic acid under different control experimental condi-
tion (explained in the material and methods). Scale bars, 50 
µm.Journal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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HA staining in poorly differentiated stromal areas Figure 4
HA staining in poorly differentiated stromal areas: Top row, (A, B, C) represents breast, stomach and gallbladder. 
Middle row, (D, E, F) represents colon, caecum and prostate. Bottom row, (G, H) represents urinary bladder and renal cell 
carcinoma. The stromal and intratumoral areas are highly positive for HA in all tumors, where as the loss of HA expression 
observed in the tumor cells. Arrow shows the tumor cells and the asterisk shows stroma. Scale bars, 50 µm.
medulloblastoma, osteosarcoma, endocervix and non-
Hodgkin's lymphoma expressed increased amount of HA
in both tumor epithelia and the intratumoral areas.
Considerable evidence has been documented the signifi-
cance of hyaluronan expression during human tumor pro-
gression where it was frequently observed in elevated
levels around tumor cells facilitating tumor migration and
proliferation [20]. High levels of HA expression correlates
with poor tumor differentiation and poor survival rates
[11,12]. Tumor cells differentiation during malignant
transformation in bronchial and squamous cell carci-
noma demonstrated the changes in HA distribution [15].
Albeit many tumor cells are enriched in HA [26], they
nonetheless showed considerable variations in HA expres-
sion depending on their origin as well as on the histolog-
ical type of the tumors [17]. Elevated levels of HA are
found in most carcinomas of squamous-cell origin, color-
ectal epithelial [11], ovarian [21] and breast [22]. On the
other hand loss of HA in progressive carcinomas from
laryngeal, esophageal, colorectal and cutaneous melano-
mas [27] was observed. This generalization, and many
years of investigations with conflicting reports on the spa-
tial distribution of hyaluronan in early and late malig-
nancy have increased the depth of the dilemma about the
role of HA during tumor progression.Journal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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This dilemma along with our previous observation of lin-
ear over expression of HA-binding protein on the tumor
cells during tumor progression prompted us to investigate
more clearly the spatial and temporal expression of HA on
both tumor cell surfaces and stroma during the progres-
sion of tumor to understand its possible role during
tumor progression. We have concentrated specifically on
well and poorly differentiated tumors from carcinomas,
sarcomas and various squamous cell carcinomas. Our
results from the present investigation clearly showed a
total absence of hyaluronan on tumor epithelia in the
poorly differentiated tumor as shown in figure 2, except in
astrocytoma (fig. 2A) and a definite trend in the contin-
ued expression of hyaluronan in the intratumoral stroma
(fig. 4). The increased accumulation of HA on tumor cells
surfaces (fig. 5) and associated stroma during early and
mid-cellular differentiation of tumors (fig. 1) of different
origins irrespective of tumor types was observed. Indeed,
in well-differentiated tumors the enriched accumulation
of hyaluronan was observed and is well in accordance
with previous investigations. However some of the poorly
differentiated tumors such as liver, gallbladder, prostate,
endocervix, ovary, testes and osteosarcoma showed negli-
gible presence stromal HA. The results of the present
investigation are condensed in to Table 1, which shows
differential HA expression between well-differentiated
and poorly differentiated tumor with respect to tumor
cells and tumor associated stroma.
The observations from our previous and present investiga-
tions as well as the observations from different laborato-
ries around the world enticed us to speculate the existence
of intricate multiple pathways towards the regulation of
HA synthesis and degradation. Such pathways might
involve temporal over-expression of Has [42]; Hyaluroni-
dase enzyme [37,40]; and HA-binding proteins [4,9] dur-
ing tumor development and progression. Evidence is
mounting that suggests the extracellular matrices degrad-
ing enzymes are involved in controlling multiple steps in
tumor invasion, metastasis and adhesion [33,34]. The
observation that the differential clinical significance of
HA and HYAL1 (Hyaluronidase 1), the correlation of
Hyaluronidase enzyme in prostate tumor, its application
for detecting intermediate and in high-grade bladder can-
cer [37] indicated the possible down regulation of HA in
poorly differentiated tumors. Additionally, it was also
shown that the accumulation of HA fragments is accom-
panied with tumor metastasis and neovascularization
[18,40]. The above observations partially answered our
questions about the loss of HA on the tumor cells during
the progression of tumor from well differentiated through
poorly differentiated stages.
There are a number of ways the high levels of HA might
promote tumorigenesis. First, the increased detachment
and motility of malignant cells during early and mid-
stages of the tumor are due to the increased accumulation
of HA, which in turn caused the deformation of restrictive
architecture of the ECM components and provides a
hydrated environment to facilitate migration of tumor
cells to distant sites [4,28-30]. Second, increase in the
interaction of HA with intracellular and surface receptors
(CDC37, IHABP, RHAMM & CD44) activates the HA
mediated signaling for the active invasive nature of the
malignant tumor cells during early stage of tumor progres-
sion. Third, increased tumor invasion and migration may
be due to increased synthesis of stromal HA through the
interactions of stromal fibroblasts with tumor cells. It is
possible that in addition to the above factors, there are key
events such as temporal expression of metalloproteinase
[31,32], the interaction between HA-HABP in early malig-
nancy and subsequent loss of this interaction during late
malignancy and the increase in stromal synthesis of HA
may regulate the tumor cell behavior during the progres-
sion of tumors. The growing evidence of the presence of
intracellular hyaluronan and its interaction with intracel-
lular hyaladherins such as CDC37, IHABP4 [5,8] and fur-
ther the subsequent loss of HA interaction with its
receptor during the late malignancy led us to compare the
distribution of H11B2C2 (one of the HA receptor detected
from IVd4 hybridoma) receptor and hyaluronan expres-
sion in multiple cancer tissues in later invasive stages.
HA on tumor epithelial cell surfaces Figure 5
HA on tumor epithelial cell surfaces: Three examples 
are shown. (A, B, C). A. Thyroid, B. Descending Colon, C. 
Urinary bladder. Tumors derived from well differentiated 
stage. Only 3 examples are shown. High accumulation of HA 
reactive materials observed on the cell surfaces of all the 
tumors. Arrows shows the cell surface. Scale bars, 50 µm.Journal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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Loss of HA in poorly differentiated tumors could be due to 
loss of HA, HA-receptor interaction and the over 
expression of H11B2C2 antigen
In accordance with our previous observations of the linear
over expression of H11B2C2 antigen recognized by IVd4
hybridoma [5] during tumor progression [9], the present
investigation showed a decline in HA expression by the
tumor cells while maintaining its presence in the tumor
associated stroma. The discovery of H11B2C2 protein is
one more addition to the previously observed HA-binding
proteins such as CDC37 and IHABP4 recognized by the
same IVd4 hybridoma. The significant physiological role
of these proteins in vertebrates is well explained [5,8]. In
the Figure 6 we have presented six poorly differentiated
tissues in an effort to demonstrate the complete loss of HA
expression and continued over-expression of H11B2C2
by the tumor cells during the progression of tumor
through the well differentiated to poorly differentiated
stage. The left column shows strong HA expression in the
stroma with reduced HA expression by the tumor cells
(Fig 6-F,G,H,I and 6J). Whereas, the right column shows
the over expression of H11B2C2 antigen on the tumor
cells (Fig 6-A,B,C,D and 6E).
The loss of hyaluronan by the tumor cells could be due to
multiple, intricate and interdependent events that takes
place during the tumor progression. The increased over -
expression of HA-receptor during the tumor progression
Table 1: Evaluation of Hyaluronan staining in various human tumor tissues with different grades:
Tumor types Grade Tumor cells Stroma
Astrocytoma WD XXXX XXX
PD XX XX
Ganglioglioma WD XXXX XX
PD X XXX
Medulloblastoma WD XXX XXX
PD Neg. XX
Thyroid (papillary) WD XXXX XXX
PD Neg. XX
Mucoepidermoid WD XXX XXX
PD X XX
Breast (infiltrating duct) WD XXXX XXXX
PD X XX
Breast (medullary) WD XXXX XXXX
Lung WD XXX XXX
PD X XXX
Stomach WD XXX XXX
PD X XX
Descending colon WD XXX XXX
PD X XXX
Caecum WD XXX XXX
PD Neg. XXX
Liver WD XXX XXX
PD Neg. X
Gall bladder WD XX XX
PD Neg. Neg.
Pancreas WD XXX XXX
PD Neg. XX
Renal cell carcinoma WD XX XXXX
PD X XXX
Nephroblastoma WD XXX XXX
PD Neg. XX
Urinary bladder WD XXX XXX
PD Neg. XX
Prostate WD XX XX
PD Neg. XX
Endocervix WD XXX XX
PD Neg. X
Ovary PD Neg. X
Testis PD Neg. X
Osteosarcoma WD XXX XXX
XXXX- very strong, XXX- strong, XX- moderate, X- weak WD-Well differentiated, PD- Poorly differentiatedJournal of Carcinogenesis 2006, 5:2 http://www.carcinogenesis.com/content/5/1/2
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might act as an interactive sink through endocytosis of
highly-expressed hyaluronan by the tumor cells and its
subsequent degradation by lysosomal hyaluronidase
could be contributing to the loss of hyaluronan in later
stages of invasive tumor cells. In support of this concept,
a number of receptors including liver endothelial cell
receptor [43] and lymph vessel receptor LYVE-1 homo-
logue of CD44 have been shown to be the most efficient
agents for internalization and degradation of Hyaluronic
acid of any origin [44]. It has been shown, the over-
expression of the receptors such as CDC37, CD44 and
RHAMM, in addition to the over-expression of Has during
early and mid differentiation of tumors [4,9,42].
Wike-Hooley [39] in 1984 observed the increased synthe-
sis of acidic hyaluronidase, which degrades hyaluronan in
the matrix and its possible correlation with tumor-aggres-
sive potential in well differentiated tumors. It is probable
that plasma derived acidic hyaluronidase were active in
well differentiated tumors while the secreted hyaluroni-
dase at near neutral activity as described in prostate [37],
brain, colon carcinomas and malignant melanomas [40]
was observed in highly advanced malignant tumors and
even during necrosis, with the loss of hyaluronan expres-
sion. However, the continuous over-expression of HA-
receptor, H11B2C2 antigen from well differentiated
through poorly differentiated stage signifies its important
role in clinical diagnosis of progressive tumors. Further
work is in progress to understand the relation ship
between synthesis of hyaluronidase, metalloproteinases
with the depletion of hyaluronan and increased expres-
sion of H11B2C2 antigen in highly aggressive tumors.
Conclusion
The present study enlighten the importance of spatial and
temporal HA expression during tumor progression. It also
explains the positive association of stromal HA expression
with invasive nature of tumors irrespective of their ori-
gins. The present study explains the differential expression
behavior of hyaluronan in well differentiated tumors in
contrast to the poorly differentiated one. The loss of
hyaluronan in poorly differentiated tumors could be due
to internalization of hyaluronan by the HA receptors in
conjunction with the increased synthesis of endogenous
Hyaluronidase enzyme. Thus the interaction between HA-
Hyaluronan receptor plays a significant role in tumor pro-
gression.
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